Mr Wu Gang
Non-Independent Non-Executive Chairman
Appointed 2 December 2025; annual-report Board.The business, the people and the ownership behind Cordlife.
Business overview
Cordlife Group provides private cord blood banking services in Asia. Its business focuses on services supporting mothers and children through its network of cord blood banking facilities.
Listed security
Board & management
Eight annual-report Board members, one separate Group CFO and the named annual-report secretary. Chen Xiaoling’s Group CEO, Singapore CEO and Executive Director roles refer to one person.
The annual report names Goh Xun Er as Company Secretary. Official announcement dated 15 July 2026 replaces her with Hon Wei Ling and states the two Company Secretaries are Cheok Hui Yee and Hon Wei Ling. The historical annual role is explicitly qualified with this later change.
Non-Independent Non-Executive Chairman
Appointed 2 December 2025; annual-report Board.Group Chief Executive Officer, Group Executive Director
Group CEO and CEO of Singapore from 5 June 2025; Group Executive Director from 17 July 2024. Single person with multiple roles.Non-Independent Non-Executive Director
Annual-report Board; appointed 1 December 2021.Independent Director
Annual-report Board; appointed 14 May 2024.Independent Director
Annual-report Board; appointed 14 November 2024; Audit and Risk Committee chairman in corporate governance report.Independent Director
Annual-report Board; appointed 14 November 2024.Independent Director
Annual-report Board; appointed 14 November 2024.Independent Director
Annual-report Board; appointed 19 February 2025.Group Chief Financial Officer
Key executive; appointed 14 August 2025. Not an additional director.Company Secretaries
Historical FY2025 annual-report role. Replaced by Hon Wei Ling effective 15 July 2026; official announcement states Company Secretaries thereafter are Cheok Hui Yee and Hon Wei Ling. Do not present Goh as current.Roles listed in Annual Report 2025; current appointments are not independently verified.
Holdings
Twenty registered/depository accounts and seventeen printed substantial-shareholder register rows at 20 March 2026 are retained, with eight capital/distribution/free-float contexts. Eligible shares 256,307,744 exclude 11,217,610 treasury shares; no subsidiary holdings.
Direct/deemed interests of Nanjing/Sanpower/Yuan, TransGlobal/Lui/Yiu, Ally Honour/Cedar Tree/Chen Yi Dan and Matinal/Kang overlap common blocks. They are not additive. Cedar Tree and Chen Yi Dan remain in the original substantial register at printed 4.99%.
Seven original rows for the Robust Plan upstream chain each show 15,920,000 deemed shares / 6.21%; original footnotes (8)–(14) state the downstream holder ceased substantial status on 24 January 2024. These are explicitly retained as historical register disclosures with a source inconsistency, not current beneficial holdings. The same source separately states the GCBC chain was removed after its 2024 disposal.
Top twenty total 235,865,920 / 92.02%; public float approximately 41.62% is a distinct measure. Original names and source spelling, including China Minsheng Investment Cop., Ltd, are retained.
Direct 51,870,000 shares; 20.24%; deemed — shares; —
At 20 March 2026 as printed. Direct and deemed stakes can overlap; do not add common blocks twice.20.24%Total interest
20.24%Total interest
Direct 71,460,300 shares; 27.88%; deemed — shares; —
At 20 March 2026 as printed. Direct and deemed stakes can overlap; do not add common blocks twice.27.88%Total interest
27.88%Total interest
4.99%Total interest
4.99%Total interest
Direct 26,202,866 shares; 10.22%; deemed — shares; —
At 20 March 2026 as printed. Direct and deemed stakes can overlap; do not add common blocks twice.10.22%Total interest
6.21%Total interest
6.21%Total interest
6.21%Total interest
6.21%Total interest
6.21%Total interest
6.21%Total interest
6.21%Total interest
256,307,744 ordinary shares (excluding treasury shares)
Shareholder percentage denominator.11,217,610 ordinary shares
Treasury shares excluded from voting/ownership denominator.Ordinary Shares
No par value, as also stated in Note 23 physical page 100.one vote per share
Ordinary issued shares; treasury excluded.1,340 shareholders; 256,307,744 shares
Original size-distribution totals.does not have any subsidiary holdings
Explicit nil disclosure under note (1).92.02%Total interest
41.62%
Approximately 41.62% held in public hands at 20 March 2026. Not equal to shares outside the top twenty.Total interests include direct and deemed holdings and may overlap across holders. These percentages should not be added together.
Registered holdings, including nominees and depositories; these do not establish ultimate beneficial ownership. As reported at 2026-03-20 · PDF p. 127
| Registered holder | Interest | Shares / units | Source |
|---|---|---|---|
| PHILLIP SECURITIES PTE LTD | 113,730,277 shares; 44.37% | PDF p. 1272026-03-20 | |
| CITIBANK NOMS SPORE PTE LTD | 74,940,873 shares; 29.24% | PDF p. 1272026-03-20 | |
| ALLY HONOUR TRADING (HK) LIMITED | 12,800,000 shares; 4.99% | PDF p. 1272026-03-20 | |
| DBS NOMINEES PTE LTD | 9,879,709 shares; 3.85% | PDF p. 1272026-03-20 | |
| MAYBANK SECURITIES PTE. LTD. | 9,485,160 shares; 3.70% | PDF p. 1272026-03-20 | |
| COOP INTERNATIONAL PTE LTD | 3,107,000 shares; 1.21% | PDF p. 1272026-03-20 | |
| TANTALUM CELLULAR PRODUCTS LLC | 2,566,972 shares; 1.00% | PDF p. 1272026-03-20 | |
| HENRY NGO | 1,700,000 shares; 0.66% | PDF p. 1272026-03-20 | |
| TAN POH LAN | 1,165,680 shares; 0.45% | PDF p. 1272026-03-20 | |
| UNITED OVERSEAS BANK NOMINEES P L | 990,550 shares; 0.39% | PDF p. 1272026-03-20 | |
| THET HNIN YI | 866,920 shares; 0.34% | PDF p. 1272026-03-20 | |
| RAFFLES NOMINEES(PTE) LIMITED | 837,829 shares; 0.33% | PDF p. 1272026-03-20 | |
| ALLSLAND PTE LTD | 809,800 shares; 0.32% | PDF p. 1272026-03-20 | |
| OCBC NOMINEES SINGAPORE PTE LTD | 635,000 shares; 0.25% | PDF p. 1272026-03-20 | |
| LIM AND TAN SECURITIES PTE LTD | 515,000 shares; 0.20% | PDF p. 1272026-03-20 | |
| LEE IN CHUN | 487,200 shares; 0.19% | PDF p. 1272026-03-20 | |
| UOB KAY HIAN PTE LTD | 363,000 shares; 0.14% | PDF p. 1272026-03-20 | |
| MOOMOO FINANCIAL SINGAPORE PTE. LTD. | 332,000 shares; 0.13% | PDF p. 1272026-03-20 | |
| CHOO BOON YONG | 328,550 shares; 0.13% | PDF p. 1272026-03-20 | |
| OCBC SECURITIES PRIVATE LTD | 324,400 shares; 0.13% | PDF p. 1272026-03-20 | |
Group structure
Sixteen distinct subsidiaries are disclosed in Note28. Macau appears on two original rows held99% through Healthbaby Hong Kong and1% through Cordlife Hong Kong; these routes are combined for one legal entity without double-counting. Both2025/2024 percentages are retained.
Note28 prints99.99% for India/Philippines while the structure chart displays99.9%; retain the detailed note percentages. Stemlife Berhad and its three subsidiaries have99.03% effective interests in the note.
Thai Stemlife is an associate held via Stemlife Berhad. The note prints39.61% Group effective interest, while the chart shows40% direct interest. Shanghai Cordlife Stem Cell Research Co., Ltd is dormant; the official22May2025 notice corrects erroneous Biomedical wording in previous annual reports without changing other information.
| Company | Market | Ownership interest |
|---|---|---|
| Cordlife (Hong Kong) LimitedAt 31 December 2025; Cord blood, cord lining, cord tissue banking and diagnostics. Held by Company. Original 2025 and 2024 percentages retained; subsidiary schedule percentages are not presumed immediate-parent percentages when the source reports Group effective holdings.PDF p. 105 | Hong Kong; equity held 2025 100%; 2024 100% | |
| Cordlife Stem Cell Technology LimitedAt 31 December 2025; Cord lining banking. Held by Company. Original 2025 and 2024 percentages retained; subsidiary schedule percentages are not presumed immediate-parent percentages when the source reports Group effective holdings.PDF p. 105 | Hong Kong; equity held 2025 100%; 2024 100% | |
| Healthbaby Biotech (Hong Kong) Co., LimitedAt 31 December 2025; Cord blood, cord lining and cord tissue banking. Held by Company. Original 2025 and 2024 percentages retained; subsidiary schedule percentages are not presumed immediate-parent percentages when the source reports Group effective holdings.PDF p. 105 | Hong Kong; equity held 2025 100%; 2024 100% | |
| Cordlife Technologies Pte. Ltd.At 31 December 2025; Cord lining banking and diagnostics. Held by Company. Original 2025 and 2024 percentages retained; subsidiary schedule percentages are not presumed immediate-parent percentages when the source reports Group effective holdings.PDF p. 105 | Singapore; equity held 2025 100%; 2024 100% | |
| CS Cell Technologies Pte. Ltd.At 31 December 2025; Investment holding. Held by Company. Original 2025 and 2024 percentages retained; subsidiary schedule percentages are not presumed immediate-parent percentages when the source reports Group effective holdings.PDF p. 105 | Singapore; equity held 2025 100%; 2024 100% | |
| Stemlife BerhadAt 31 December 2025; Cord blood banking. Held by Company. Original 2025 and 2024 percentages retained; subsidiary schedule percentages are not presumed immediate-parent percentages when the source reports Group effective holdings.PDF p. 105 | Malaysia; equity held 2025 99.03%; 2024 99.03% | |
| Shanghai Cordlife Stem Cell Research Co., LtdAt 31 December 2025; Dormant. Held by Company. Original 2025 and 2024 percentages retained; subsidiary schedule percentages are not presumed immediate-parent percentages when the source reports Group effective holdings.PDF p. 105 | People’s Republic of China; equity held 2025 100%; 2024 100% | |
| Cordlife Sciences (India) Pvt. Ltd.At 31 December 2025; Cord blood, cord lining, cord tissue banking and diagnostics. Held by CS Cell Technologies Pte Ltd. Original 2025 and 2024 percentages retained; subsidiary schedule percentages are not presumed immediate-parent percentages when the source reports Group effective holdings. Note 28 prints 99.99% in both years; structure chart rounds/displays 99.9%, so the precise note value is retained.PDF p. 106 | India; equity held 2025 99.99%; 2024 99.99% | |
| Cordlife Medical Phils., IncAt 31 December 2025; Cord blood, cord lining, cord tissue banking and diagnostics. Held by CS Cell Technologies Pte Ltd. Original 2025 and 2024 percentages retained; subsidiary schedule percentages are not presumed immediate-parent percentages when the source reports Group effective holdings. Note 28 prints 99.99% in both years; structure chart rounds/displays 99.9%, so the precise note value is retained.PDF p. 106 | Philippines; equity held 2025 99.99%; 2024 99.99% | |
| PT. Cordlife PersadaAt 31 December 2025; Cord blood, cord lining, cord tissue banking and diagnostics. Held by CS Cell Technologies Pte Ltd. Original 2025 and 2024 percentages retained; subsidiary schedule percentages are not presumed immediate-parent percentages when the source reports Group effective holdings.PDF p. 106 | Indonesia; equity held 2025 67%; 2024 67% | |
| CL Biotech Company LimitedAt 31 December 2025; Consulting, medical/pharmaceutical research and development. Held by CS Cell Technologies Pte Ltd. Original 2025 and 2024 percentages retained; subsidiary schedule percentages are not presumed immediate-parent percentages when the source reports Group effective holdings.PDF p. 106 | Vietnam; equity held 2025 100%; 2024 100% | |
| Hong Kong Stem Cell Regeneration Company LimitedAt 31 December 2025; Dormant. Held by Cordlife Stem Cell Technology Limited. Original 2025 and 2024 percentages retained; subsidiary schedule percentages are not presumed immediate-parent percentages when the source reports Group effective holdings.PDF p. 106 | Hong Kong; equity held 2025 100%; 2024 100% | |
| Stemlife Properties Sdn. Bhd.At 31 December 2025; Property investment. Held by Stemlife Berhad. Original 2025 and 2024 percentages retained; subsidiary schedule percentages are not presumed immediate-parent percentages when the source reports Group effective holdings.PDF p. 106 | Malaysia; equity held 2025 99.03%; 2024 99.03% | |
| Stemlife Therapeutics Sdn. Bhd.At 31 December 2025; Cord lining and cord tissue banking. Held by Stemlife Berhad. Original 2025 and 2024 percentages retained; subsidiary schedule percentages are not presumed immediate-parent percentages when the source reports Group effective holdings.PDF p. 106 | Malaysia; equity held 2025 99.03%; 2024 99.03% | |
| Stemlife Biotechnology Sdn. Bhd.At 31 December 2025; Medical laboratory, diagnostics and general medical screening. Held by Stemlife Berhad. Original 2025 and 2024 percentages retained; subsidiary schedule percentages are not presumed immediate-parent percentages when the source reports Group effective holdings.PDF p. 106 | Malaysia; equity held 2025 99.03%; 2024 99.03% | |
| Healthbaby Biotech (Macau) Co., LimitedAt 31 December 2025; Marketing services; original two ownership routes combined for one legal entity. Held by Healthbaby Biotech (Hong Kong) Co., Limited (99%) and Cordlife (Hong Kong) Limited (1%). Original 2025 and 2024 percentages retained; subsidiary schedule percentages are not presumed immediate-parent percentages when the source reports Group effective holdings.PDF p. 106 | Macau; equity held 2025 99 + 1%; 2024 99 + 1% | |
| Thai Stemlife Co., LtdHeld by Stemlife Berhad. Cord blood banking services. Structure chart shows direct stake 40%; 40% × 99.03% = 39.612% Group effective holding rounded39.61%. This is an associate, not a subsidiary.PDF p. 87 | Thailand; effective ownership 2025 39.61%; 2024 39.61% | |
Ownership interests and geographic information follow the annual report. Comparative years and footnote markers retain the report’s notation.
Senior executives
| Item | Value | Period / scope | Source |
|---|---|---|---|
| Ms Wu Yifei | Group Chief Financial Officer | PDF p. 21 |
Extracted from Annual Report 2025 and checked against the cited pages; see the original report for full context.
Related parties, people & properties
| Item | Value | Period / scope | Source |
|---|---|---|---|
| Interested person transactions | There were no interested person transactions amounting to S$100,000 or more for the financial year reported on. | Group, FY2025 | PDF p. 43 |
| Item | Value | Period / scope | Source |
|---|---|---|---|
| Status of Claims against the Company | the Company has received claims from the Company’s customers alleging the damage of cord blood units | Company, FY2025 | PDF p. 119 |
| Contingent liabilities - financial impact | the Company is at present unable to assess the financial impact arising therefrom | Group, FY2025 | PDF p. 122 |
| Investigation by Commercial Affairs Department | the CAD had not imposed any further directives and/or penalties on the Company in relation to the Investigations | Company, FY2025 · As at 2025-12-31 | PDF p. 122 |
| Item | Value | Period / scope | Source |
|---|---|---|---|
| Dr Xu, Tianhong | 50,000 S$ | Director, FY2025 | PDF p. 35 |
| Gao Xiang | 50,000 S$ | Director, FY2025 | PDF p. 35 |
| Dr Wang Xiaorui | 50,000 S$ | Director, FY2025 | PDF p. 35 |
| Sim Sze Kuan | 50,000 S$ | Director, FY2025 | PDF p. 35 |
| Yuen Wai | 43,333 S$ | Director, FY2025 | PDF p. 35 |
| Wu Gang (1) | 7,971 S$ | Director, FY2025 | PDF p. 35 |
| Zhai Lingyun (6) | 48,551 S$ | Director, FY2025 | PDF p. 35 |
| Top three key management personnel aggregate remuneration | S$661,343 | Top three key management personnel excluding GCEO and ED, FY2025 | PDF p. 36 |
| Item | Value | Period / scope | Source |
|---|---|---|---|
| Unit 6.06, Wisma Perintis, Jalan Dungun, Damansara Heights, 50490 | Freehold | Group, investment property, 31 December 2025 · As at 2025-12-31 | PDF p. 91 |
| B-1-8, Greentown Square, Jalan Dato Seri Ahmad Said, 30450 Ipoh, Perak | Leasehold; 99 years | Group, investment property, 31 December 2025 · As at 2025-12-31 | PDF p. 91 |
| No. 220, Jalan Burma, 10350 Penang | Freehold | Group, investment property, 31 December 2025 · As at 2025-12-31 | PDF p. 91 |
| B-2-8, Greentown Square, Jalan Dato Seri Ahmad Said, 30450 Ipoh, Perak | Leasehold; 99 years | Group, investment property, 31 December 2025 · As at 2025-12-31 | PDF p. 91 |
| B-3-8, Greentown Square, Jalan Dato Seri Ahmad Said, 30450 Ipoh, Perak | Leasehold; 99 years | Group, investment property, 31 December 2025 · As at 2025-12-31 | PDF p. 91 |
| Item | Value | Period / scope | Source |
|---|---|---|---|
| CBBS Licence renewal after year end | the Company’s CBBS Licence has been renewed for a period one (1) year from 14 January 2026 to 13 January 2027 (both dates inclusive) | Company, after 31 December 2025 | PDF p. 121 |
| Item | Value | Period / scope | Source |
|---|---|---|---|
| Group CEO's message - looking ahead | the worst is behind us | Group CEO, FY2025 report | PDF p. 7 |
Extracted from Annual Report 2025 and checked against the cited pages; see the original report for full context.
Corporate information